Bone Therapeutics SA

Transparency notification received from S.R.I.W. SA and Sofipôle SA

Regulated information

Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings

Gosselies, Belgium, 9 December 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces that it has received a transparency notification dated 3 December 2019 indicating that the shareholdings held by S.R.I.W. SA (Société Régional d’Investissement de Wallonie) and its subsidiary Sofipôle SA (Société Wallonne pour le Financement des Infrastructures des Pôles de Compétitivité) have passively crossed the threshold of 10% as a result of the issuance of new shares on 14 November 2019 following the conversion of convertible bonds issued on the private placement on 7 March 2018.

The notification dated 3 December 2019 contains the following information:

• Reason for the notification: Passive crossing of a threshold
• Notification by: A parent undertaking or a controlling person
• Persons subject to the notification requirement: S.R.I.W. SA & Sofipôle SA
• Transaction date: 14 November 2019
• Threshold that is crossed: 10%
• Denominator: 10,620,686
• Notified details:

Voting rights	Previous notification	After the transaction
Holders of voting rights	# of voting rights	# of voting rights	% of voting rights
S.R.I.W. SA	344,530	344,530	3.24%
Sofipôle SA	703,823	703,823	6.63%
Total voting rights held by S.R.I.W and Sofipôle	1,048,353	1,048,353	9.87%

·Full chain of controlled undertakings through which the holding is effectively held: The Walloon Region holds 99.43% of S.R.I.W. SA which controls 60% of the shares of Sofipôle SA.

The notification can be consulted on the website of Bone Therapeutics, under the heading “Shareholder information”.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.